Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

Only standard information required at REACH Annex VIII is available for assessing the toxicokinetics for the test substance. The available test data do not permit extensive conclusions concerning absorption, metabolism or excretion to be conclusively drawn. Acute toxicity via the oral route was observed although low toxicity was observed in the available OECD 422 study (repeated dose/repro screening study) which was conducted at the maximum tolerable dose owing to the corrosive nature of the test substance. An in vivo chromosome aberration assay conducted in Chinese Hamsters demonstrated exposure with clinical signs and mortality evident.

Key value for chemical safety assessment

Bioaccumulation potential:
low bioaccumulation potential

Additional information

Repeated oral administration of the test substance (in an OECD 422 study) to rats provided a parental NOAEL of 2 mg/kg/day. This was the maximum feasible dose that could be tested owing to the corrosive nature of the test substance. In a previously conducted acute oral toxicity study (preceding current testing guidelines) and in the range finder for the OECD 422 study, symptoms of corrosive effects and systemic toxicity were noted indicating that absorption and distribution of the test substance can be expected at doses where corrosive effects are observed. Based on the relatively low Log Kow values (<4.5), bioaccumulation of the test substance is not expected.

Acute oral toxicity of the test substance was observed (LD50 124 mg/kg) alongside acute toxicity via inhalation (although lacking the required detail for REACH purposes).

No treatment related changes were observed in any of the developmental or reproductive parameters in the OECD 422 study, possibly indicating low adsorption through the placenta to directly affect the foetuses and similarly as no effects were observed in pups during the lactation phase, low exposure to the developing pups via lactation is likely. This may be a result of the low feasible dose that was used on study.

The single dose in vivo chromosome aberration study in Chinese Hamsters provided evidence of adsorption and systemic exposure as significant clinical signs were noted alongside mortality.